التفاصيل البيبلوغرافية
| العنوان: |
Autologous Haematopoietic Stem Cell Transplantation for Refractory Crohn's Disease: Efficacy in a Single-Centre Cohort. |
| المؤلفون: |
López-García, Alicia, Rovira, Montserrat, Jauregui-Amezaga, Aranzazu, Marín, Pedro, Barastegui, Rebeca, Salas, Azucena, Ribas, Vicent, Feu, Faust, Elizalde, J. Ignasi, Fernández-Avilés, Francesc, Martínez, Carmen, Gutiérrez, Gonzalo, Rosiñol, Laura, Carreras, Enric, Urbano, Alvaro, Lozano, Miguel, Joan Cid, Suárez-Lledó, María, Masamunt, Maria Carme, Comas, Dolors |
| المصدر: |
Journal of Crohn's & Colitis; Oct2017, Vol. 11 Issue 10, p1161-1168, 8p |
| مستخلص: |
Background: Haematopoietic stem cell transplantation [HSCT] is considered a therapeutic option for patients with severe Crohn's disease [CD] unresponsive to currently available therapies. Methods: Autologous HSCT was considered for CD patients with active disease, unresponsive or intolerant to approved medications and unsuitable for surgery. After HSCT, patients were closely followed up every 6 weeks during the first 2 years and every 6 months thereafter up to 5 years. Colonoscopy and/ or magnetic resonance imaging were performed at Months 6, 12, 24, and 48 after HSCT. Results: From December 1, 2007 to December 31, 2015, 37 CD patients were assessed for HSCT. Of these, 35 patients [13 within the ASTIC trial] underwent mobilisation. Six patients did not complete the transplant for various reasons and 29 patients were finally transplanted. Patients were followed up during a median of 12 months [6-60]. At 6 months, 70% of patients achieved drug-free clinical remission (Crohn's Disease Index of Severity [CDAI] < 150). The proportion of patients in drug-free remission (CDAI < 150, Simple Endoscopic activity Score [SES]-CD < 7] was 61% at 1 year, 52% at 2 years, 47% at 3 years, 39% at 4 years, and 15% at 5 years. Patients who relapsed were re-treated and 80% regained clinical remission. Six out of the 29 [21%] required surgery. One patient died due to systemic cytomegalovirus infection 2 months after transplant. Conclusions: HSCT is a salvage therapy for patients with extensive and refractory CD. Although relapse occurs in a majority of patients within 5 years after transplant, drug responsiveness is regained and clinical remission achieved in 80% of cases. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Crohn's & Colitis is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Supplemental Index |
